and (xviii) PHYSIOLOGY. ' Estrogen receptor (ER) ␤ counteracts the activity of ER␣ in many systems. In agreement with this, we show in this study that induced expression of ER␤ in the breast cancer cell line T47D reduces 17␤-estradiol-stimulated proliferation when expression of ER␤ mRNA equals that of ER␣. Induction of ER␤ reduces growth of exponentially proliferating cells with a concomitant decrease in components of the cell cycle associated with proliferation, namely cyclin E, Cdc25A (a key regulator of Cdk2), p45 Skp2 (a key regulator of p27 Kip1 proteolysis), and an increase in the Cdk inhibitor p27 Kip1 . We also observed a reduced Cdk2 activity. These findings suggest a possible role for ER␤ in breast cancer and imply that ER␤-specific ligands may reduce proliferation of ER-positive breast cancer cells through actions on the G 1 phase cell-cycle machinery.
cell cycle ͉ p27 ͉ cyclin E ͉ Cdc25A ͉ Cdk2 T he proliferative actions of 17␤-estradiol (E2) mediated via estrogen receptor (ER) ␣ can be opposed by ER␤. The mechanism behind this antagonism seems to be related to the different actions of E2-ER␣ and E2-ER␤ complexes at AP-1 sites, respectively (1) . This antiproliferative effect of ER␤ might explain protection by estrogen against development of colon cancer, which has been seen in women on hormone replacement therapy (2) and may be of significance in the progression of colon cancer, where it has been shown that the malignant cells in the colon lose expression of ER␤ (1) . The ventral prostate and the uterus are other tissues where ER␤ exerts antiproliferative actions. In the absence of ER␤ (in ER␤Ϫ͞Ϫ mice), there is hyperplasia of the prostate epithelium (2) and hypersensitivity of the uterus to the growth effects of E2 (3) .
Breast cancer cell lines are extensively used as model systems to study aberrant E2-dependent and E2-independent growth. One commonly used cell line whose growth is stimulated by E2 is the ER␣-positive cell line T47D (3, 4) . E2 regulates expression of key cell-cycle genes such as c-Myc, cyclin D1, cyclin E, A, Cdc25A, p45 Skip2 , and p27 Kip1 (5) (6) (7) (8) (9) (10) . The cyclin D promoter is one site where ER␤ opposes ER␣-mediated activation and the ER␤-antiestrogen complex can stimulate transcription (1). Increased transcription of the cyclin D genes occurs 3-4 h after E2 exposure of cells (10) . Its transcription is reduced by antiestrogens, and this reduction in levels of cyclin D1 contributes to reduced cell proliferation (11) . Another indication of the importance of cyclin D1 in E2 signaling is that its overexpression in breast cancer cells leads to resistance to antiestrogens (12) .
Cyclins E and A are important later in the G 1 phase of the cell cycle when they participate in activation of Cdk2, a crucial step in moving the cell into the S phase of the cell cycle (13) . Another factor that is essential for activation of Cdk2 activity is the phosphatase Cdc25A, which is itself induced by E2 (10) . Inhibitors of Cdk2 also play an important role in cell-cycle regulation. p27
Kip1 is one such inhibitor. In its turn, level of p27 Kip1 is regulated by ubiquitin-induced degradation, which is mediated by p45 Skip2 (14) ; when p45 Skip2 is overexpressed, levels of the cell-cycle inhibitor p27
Kip1 are reduced and the cell becomes resistant to antiestrogens.
In a recent report, Omoto et al. (15) expressed ER␤ stably in MCF-7 cells under the control of a cytomegalovirus promoter and found that the receptor had a negative effect on proliferation of these cells and reduced the number of colonies in an anchorage-independence assay.
In the present study, we have investigated how ER␤ affects cellular proliferation in response to E2 in T47D cells stably transfected with tetracycline-regulated ER␤ expression plasmid. We have investigated the specific effects of ER␤ expression on the components of the cell cycle machinery Cdk2, cyclin D1, Cdc25A, cyclin E, and p27
Kip1 in these cells.
Materials and Methods
Cell Culture. T47D cells were cultured in DMEM͞Ham's F-12 (1:1) supplemented with 5% FBS, penicillin, and streptomycin. For experiments using E2, DMEM without phenol red and FBS treated with Dextran-coated charcoal (DCCFBS) were used.
Transfection and Plasmids. T47D cells stably transfected with tetracycline-regulated ER␤ expression plasmid were generated in two steps. The cells were first transfected with pTet-tTAk (GIBCO͞BRL) modified to contain puromycin resistance by using Lipofectin according to the manufacturer's instructions (GIBCO͞BRL). Selection was performed with 0.5 g͞ml puromycin in the presence of 1 g͞ml tetracycline. A clone showing high levels of induction upon tetracycline withdrawal and low basal activity was selected by using the pUHC13-3 control plasmid (GIBCO͞BRL). The short form of ER␤ encoding 485 aa was fused to the flag tag (ER␤ 485) and cloned into PBI-EGFP (Clontech). This construct was then transfected into the previously described inducible clone together with a neomycin resistance plasmid, and selection was performed with 500 g͞ml G418 (Calbiochem). For transient transfections of promoter constructs, normal T47D cells were used. Cells were plated in six-well plates at 50% confluency and synchronized as described under real-time PCR and primers (see below). The plasmids were transfected with Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions.
Real-Time PCR and Primers. Cells were added to six-well plates at a confluency of 40%; after 1 day, the normal medium was replaced by phenol red-free medium supplemented with 5% DCCFBS. After 24 h, 10 nM ICI 182,780 was added to the cultures, and incubation proceeded for an additional 48 h. For expression of ER␤, tetracycline was removed 12 h before initiation of treatment with E2. At time 0 h, the medium was changed to 0.5% DCCFBS, and E2 was added to a final concentration of 10 nM. RNA was prepared by adding 1 ml of TRIzol (Invitrogen) to each 35-mm plate at different time points after the start of treatment, and RNA was prepared according to the manufacturer's instructions. cDNA (100 ng) was amplified in a real-time PCR using TaqMan Universal Master Mix (PE Applied Biosystems) or, for cyclin E, QPCR Master Mix for Cybergreen (Medprobe). The real-time PCRs were performed in an ABI PRISM model 7700 sequence detector (Perkin-Elmer Applied Biosystems) under the following conditions: 50°C for 2 min, 95°C for 1 min, followed by 40 cycles at 95°C for 15 sec and 60°C for 1 min. The optimum concentration of primers and probes was determined in preliminary experiments. All probes were labeled with 6-carboxyfluorescein as the 5Ј reporter. The sequences of primers and probes are as follows. H cyclin D1 (16) ; probe, 5Ј-TCCT-GATGCTCCTGTCCCACGTCA; 100 nM primers, 100 nM probe. H ERa: F, 5Ј-ATCCTGATGATTGGTCTCGTCT-3Ј; R, 5Ј-GGATATGGTCCTTCTCTTCCAGA-3Ј; probe, 5Ј-GGC-TACATCATCTCGGTTCCGCAT; 300 nM primers, 300 nM probe. H cyclin E: F, 5Ј-GGAAGAGGAAGGCAAACGTGA; R, 5Ј-TCGATTTTGGCCATTTCTTCAT; 300 nM primers. Real-time PCR was done in triplicate. The 18S rRNA (PDAR, Perkin-Elmer Applied Biosystems) was used as a reference gene.
Proliferation Assay. Cells were plated at a density of 10,000 cells per cm 2 . After 24 h, the medium was replaced with stripped medium (phenol red-free medium supplemented with 5% DCCFBS, 1% penicillin-streptomycin, 0.1% kanamycin) and 10 nM ICI 182,780. After an additional 48 h, the cells were washed with PBS, and medium containing 0.5% DCCFBS was added in combination with different treatments (with͞without E2, 4OH-tamoxifen, raloxifene, and ICI 182,780). Tetracycline was maintained in the medium or removed as indicated in the figure legends. After 6 days of growth, proliferation assay was performed as described.
Western Blot, Antibodies, and Kinase Assays. Cells were grown to 50% confluency on a 100-mm tissue culture plate (Corning). Cultures were mitogen-starved as described above. After treatment with E2 or 4OH-tamoxifen for the indicated times, the cells were washed with PBS, and 200 l of Nonidet P-40 lysis buffer (0.2% Nonidet P-40͞225 mM NaCl͞25 mM Tris, pH 7.4) was added. The cells were harvested with a rubber policeman, and the cell slurry was sonicated briefly before centrifugation at 13,000 ϫ g for 5 min at 4°C. The supernatant was collected, and aliquots of 25 g of protein were separated on SDS͞PAGE. Antibodies used were as follows: mouse mAbs directed against Cdc25A (Ab-3) and E2F-1 (Ab-1) (NeoMarkers, Fremont, CA), cyclin D1 rabbit polyclonal antibody (sc-753), mouse monoclonal anticyclin E (HE12) and cyclin A (BF683), goat polyclonal anti-p27 Kip1 (C19), and rabbit polyclonal anti-Skp2 (H435) (Santa Cruz Biotechnology). Histone kinase assays were performed as described (9, 17) , using rabbit polyclonal antibodies to Cdk2 (M2) (Santa Cruz Biotechnology).
Flow Cytometric Analysis. For flow cytometric analysis, T47D cells were harvested in saline-EDTA, fixed in cold 70% ethanol, and stored at Ϫ20°C. Fixed cells were subsequently washed, treated with 100 g͞ml RNase A, and stained with 50 g͞ml propidium iodide. Analysis of DNA content was performed in a Becton Dickinson FACScan with a minimum of 15,000 events collected for analysis with Becton Dickinson CELLQUEST software. The proliferative fraction in the culture was determined as cells in the S and G 2 ͞M phases of the cell cycle based on DNA content.
Results

ER␤ Expression Inhibits Proliferation of T47D
Cells. T47D cells proliferate in response to treatment with E2 (5). In breast cancer cell lines, ER␣ has been shown to be the receptor responsible for the proliferative effect of E2, whereas, based on studies from knockout mice, ER␤ has been proposed to reduce ER␣-induced proliferation (18) . With real-time PCR using oligos specific for ER␣ and ER␤, respectively, we found that the predominant ER mRNA in T47D cells is ER␣, the ratio ER␣͞ER␤ mRNA being 9:1. We could not detect any endogenous expression of ER␤ protein in these cells (data not shown).
There is a lack of suitable breast cancer cell lines for studies on the function of endogenous ER␤. Our approach has been to stably transfect the breast cancer cell line T47D with a tetracycline-regulated vector for expression of ER␤. In these cells, we can regulate the expression level of the receptor by using different amounts of tetracycline (Fig. 1) . We found that E2 inhibited proliferation of T47D cells completely when the mRNA levels of both receptors are equal (Figs. 1a and 2 ) in contrast to parental T47D cells where ER␣ predominates and E2 acts as a mitogen. Levels of ER␤ protein detected with FLAG antibodies correlated well with ER␤ mRNA expression (Fig. 1b) .
Cyclin D1 and Cdc25A mRNA Levels Are Affected by ER␤ Expression.
Real-time PCR and Western blot analysis of cyclin D1 and Cdc25A expression were performed on extracts of mitogendeprived T47D cells treated with E2 for different lengths of time. We could show that cyclin D1 mRNA and protein are induced in response to E2 treatment, when the ratio of ER␤ to ER␣ is 4:1 (Fig. 3) . Furthermore, in the presence of tetracycline (i.e., with ER␤ expression suppressed), Cdc25A mRNA and protein are induced by E2 within 12 h of treatment of ICI 182,780 pretreated cells. When tetracycline was absent (ER␤ expressed), induction of Cdc25A mRNA and protein was weak (Fig. 4) . To investigate whether regulation occurred at the transcriptional level, we transiently transfected a luciferase reporter regulated by a minimal Cdc25A promoter into T47D cells. The cells had been treated with ICI 182,780 in low serum for 48 h. The basal activity of the Cdc25A promoter was unchanged by cotransfection with ER␤, but upon treatment with 10 nM E2, there was a substantial decrease in promoter activity (Fig. 5) . In agreement with a study by Hodges et al. (11) , 4OH-tamoxifen induced the promoter to the same extent as E2 in cells maintained in tetracycline, whereas expression of ER␤ eliminated this induction (Fig. 5) . Activity of Cdk2 complexes precipitated from cells expressing ER␤ was markedly decreased relative to those from cells treated with E2 in the absence of ER␤, causing a decrease of cells in the proliferative fraction SϩG 2 ͞M (Fig. 6) . These complexes could not be activated by adding purified GSTCdc25A (data not shown). A similar inability of Cdc25A to activate Cdk2 was observed by Musgrove et al. (19) with progestin inactivated Cdk2. Levels of the Cdk inhibitor p27 kip1 increased in ER␤-expressing cells and did not decline in re- Fig. 2 . Expression of ER␤ inhibits E2-stimulated proliferation. T47D ER␤ cells were spread on 24-well plates and synchronized as described. The wells were washed with PBS and medium containing 10 nM E2, 0.5% DCCFBS, and 2,000, 10, 6, 2, or 0 ng of tetracycline͞ml. The plates were then placed in an incubator for 5 days, whereupon proliferation assay was performed as described in Materials and Methods. Fig. 3 . ER␤ regulates cyclin D1 expression in response to E2 treatment. (a) T47D ER␤ cells were spread on six-well plates at a low confluency (40%) and grown as described in Materials and Methods. Tetracycline was removed 12 h before start of treatment with 10 nM E2. Cells was harvested in TRIzol at different time points, and cDNA for real-time PCR was prepared; each point represents an average of two different cDNA preparations. (b) Whole-cell extracts were prepared from synchronized T47D ER␤ cells grown on 100-mm plates as described in Materials and Methods. Proteins (50 g) were separated on SDS͞PAGE and electrotransferred to nitrocellulose membrane, and cyclin D1 protein was detected by using antibody directed against cyclin D1 (rabbit polyclonal antibody sc753, Santa Cruz Biotechnology). sponse to E2 (Fig. 6) as we have demonstrated in previous studies with MCF-7 cells (9, 17) . Expression of p45
Skp2 , a key component in ubiquitin͞proteosome-mediated p27
Kip1 proteolysis in breast cancer cells (8) , was decreased as were cyclin A and E2F-1 (Fig. 6) .
ER␤ Inhibits E2 Induction of Cyclin E. Cyclin E is necessary for activation of Cdk2. Because we found that purified GST Cdc25A could not rescue the inhibited Cdk2 complex precipitated from ER␤-expressing cells, we investigated whether the level of cyclin E was reduced by the activation of ER␤. We found that, as expected, cyclin E was up-regulated by E2 at both mRNA and protein levels in control T47D cells. However, expression of ER␤ inhibited the E2 induction of cyclin E mRNA͞protein (Figs. 6 and 7 a and b). Cyclin A mRNA was regulated in the same way as cyclin E by ER␤ (data not shown). In transient transfections, the cyclin E promoter was induced by E2 in control cells, but in ER␤-expressing cells it was repressed (Fig. 7c) .
Antiestrogens Do Not Induce Proliferation in the Presence of ER␤ in
T47D Cells. Because ER␤ can activate AP-1 in the presence of antiestrogens (20) , it could be argued that the receptor would stimulate proliferation in the presence of antiestrogens. In the presence of 2 g͞ml tetracycline (no ER␤ expression), E2 induced proliferation Ͼ2-fold, whereas 1 M 4OH-tamoxifen and raloxifene stimulated proliferation only weakly, and ICI 182,780 did not. The weak stimulation by 4OH-tamoxifen is likely caused by the weak agonistic of this agent on ER␣ (21) . Expression of ER␤ completely prevented proliferation in response to E2, 4OH-tamoxifen, raloxifene, and ICI 182,780 (Fig. 8) .
Discussion
We have shown here that expression of ER␤ in the breast cancer cell line T47D inhibits proliferation in response to E2 treatment. By monitoring cell-cycle components, we found that, surprisingly, cyclin D1 is induced earlier and to a higher level if ER␤ is expressed. This finding is in apparent contradiction with the current hypothesis (based on analysis with the Ϫ936 cyclin D1 promoter) that ER␤ inhibits proliferation of breast cancer cells by reducing E2-mediated induction of cyclin D1 (1, 22) . The reason for the discrepancy might be that additional regulatory elements situated further upstream or downstream of the cyclin D1 gene are targets of regulation by ER␤. Furthermore, the studies referred to (13, 22) used HeLa cells, which lack endogenous ER, and, in this system, the activity of ER may be different from that in T47D cells where ER is naturally expressed. Although it is well established that E2 activates the cyclin D1 promoter (22) , E2 induces cyclin D1 mRNA and protein in MCF-7 cells within 3-4 h of stimulation of quiescent cells (10) , indicating that induction of cyclin D1 is not an early event in entry of cells into the cell cycle. The importance of cyclin D1 expression is illustrated by studies indicating that the major antiproliferative effect of tamoxifen is related to its inhibition of cyclin D1 expression (11) and that overexpression of cyclin D1 or c-Myc is sufficient to increase the proliferation of MCF-7 cells (23) . However, this is not the case in all situations: when ER␣ was expressed from an adenovirus vector in the breast cancer cell line MDA-MB-231, there was increased expression of cyclin D1 but a reduction in proliferation (24) .
In MCF-7 cells, ER␣ is known to induce expression of c-Myc and E2F-1, which are, in turn, important for E2 induction of Cdc 25A mRNA and protein levels (9, 25) . In contrast, we found that ER␤ expression in T47D cells results in repression of Cdc 25A mRNA and protein expression. The inhibited Cdk2 complex precipitated from ER␤-expressing cells could not be activated with purified GST-Cdc25A (data not shown), indicating that, as shown in other studies (11, 19) , Cdc25A is not solely responsible for the lack of Cdk2 activation. A further examination of the regulation by ER␤ of other cell-cycle factors revealed that expression of both cyclin E and cyclin A mRNA was decreased by ER␤. Cyclins E and A are critical components of the active Cdk2 complex driving passage from G 1 into S phase. Overexpression of cyclins E or A is associated with poor prognosis in breast cancers (26) (27) (28) (29) . We cannot at this stage discriminate between the alternative possibilities that the reduction in cyclin E and A levels is caused (i) by ER␤'s inhibition of ER␣'s transcriptional activity or (ii) by ER␤ directly repressing the activity of the cyclin E and A promoters. There is no evidence at this time that ER␣ or ER␤ binds directly or indirectly to enhancer elements in the cyclin E or A promoters.
Inhibition of expression of cyclin E, cyclin A, Cdc25A, and E2F-1 does not necessarily indicate a direct regulation by ER␤. It may simply be an indication that the cells are arrested in G 1 phase (9) . Because expression of all of these cell cycle-associated factors is regulated by E2F-dependent mechanisms, the effect of ER␤ activation on G 1 -phase regulators may be the consequence of cell-cycle inhibition and a lack of release from E2F͞pocket protein transcriptional repression. Such cell-cycle inhibition may result from a failure to down-regulate Cdk inhibitors such as p27 Kip1 (Fig. 6) , whose regulation in MCF-7 breast cancer cells is cell cycle independent (8, 9) . This failure in down-regulation of p27
Kip1 may, in turn, reflect the observed decrease in p45 Skp2 levels (Fig. 6) . We have previously shown that E2 up-regulates p45 Skp2 expression and elicits nuclear export of p27 Kip1 in MCF-7 cells, leading to degradation of this Cdk inhibitor in both nucleus and cytoplasm (8) .
It is clear that active cyclin E-Cdk2 is essential for the formation of the origins of replication complexes when cells reenter the cell cycle from a quiescent state, but several recent studies have raised questions about the primacy of cyclin E-Cdk2 in regulating G 1 ͞S transition in continuously proliferating mouse embryo fibroblasts and colon cancer cells (30) (31) (32) (33) (34) . In breast cancer cells, Cdk2 activity does not necessarily correlate with cyclin E levels (35) and may instead reflect the relative amounts of cyclin E and p27Kip1 (36) . Cdk2 activity is turned on in quiescent MCF-7 cells by E2 without significant changes in cyclin E expression and instead relates to changes in association of cyclin E-Cdk2 with CIP͞KIP Cdk inhibitors (37) .
Our observation that the cyclin E content of Cdk2 immunoprecipitates was unchanged by ER␤ expression (Fig. 6 ) leaves it unclear as to whether cyclin E suppression is the primary cause of the low Cdk2 activity in ER␤-expressing cells. The basis of Cdk2 and cell-cycle inhibition in ER␤-expressing T47D cells thus remains to be fully characterized.
Under our experimental conditions, antiestrogens like 4OH-tamoxifen, raloxifene, and ICI 182,780 did not increase proliferation of cells expressing ER␤ at high levels. This finding was surprising because the antiestrogen-ER␤ complex is known to activate AP-1 sites. Clearly, the interaction of ER␤ with antiestrogens is not sufficient to increase proliferation in T47D cells.
Palmieri et al. (38) have studied the expression of both ER␣ and ER␤ in ductal cancers of various grades and shown that although ER␤ is the dominant receptor in normal breasts, it is not expressed in grade 1 ductal cancer. Grade 1 ductal cancer shows high expression of ER␣, and these are the cancers that respond well to tamoxifen. In grade 2 ductal cancer, both ER␣ and ER␤ are highly expressed, whereas in grade 3 ductal cancer, which has the poorest prognosis, there is commonly neither ER␣ nor ER␤ (38) . Fuqua et al. (39) , analyzing 242 breast tumors with a monoclonal antibody against the N terminus of ER␤, showed that this receptor isoform is present in 62% of the cases expressing ER␣. No correlation of ER␤ expression with tumor grade or S-phase fraction was observed; the study, however, did not take the relative levels of the receptors into consideration. Another study by Iwao et al. (40) using 112 breast tumors showed 8 . ER␤ inhibits proliferation using 10 nM E2 or 1 M solutions of the antiestrogens 4OH-tamoxifen, raloxifene, and ICI182,780. T47D ER␤ cells were spread onto 24-well plates and synchronized as described in Materials and Methods. Treatment was started as indicated, the cells were harvested after 5 days, and proliferation assay was performed as described. Each bar represents an average of measurements from six wells.
that, whereas ER␣ mRNA is up-regulated during the progression of ER-positive breast cancers, ER␤ mRNA is downregulated. It is now clear that it is insufficient to measure only one form of ER␤ in breast cancer. Another ER␤ splice variant, ER␤ cx (41) , is well expressed in breast cancer (42) , which is important because if ER␤ cx is expressed in the same cells as ER␣, it quenches ER␣ action (41) . Any meaningful study on the relationship between ER expression and prognosis with antiestrogen treatment must measure ER␣, ER␤, and ER␤ cx and, in addition, must examine the cellular localization of these receptors.
Our studies were done in cells coexpressing ER␣ and ER␤ and show that when these two receptors are together in a cell ER␤ can inhibit the proliferative response of ER␣ to E2.
